Aurinia Pharmaceuticals (AUPH) has been in the news for a couple of reasons over the past few weeks. First there were rumors the biotech was a bolt on accusation target for Novartis, marking another instance of a pharma giant showing interest in Aurinia. Then, the company released positive topline results from the AURORA 2 continuation study. This is an investigation of the long-term safety and tolerability of Lupkynis (voclosporin), Aurinia’s treatment for adults with active lupus nephritis (LN). However, for Oppenheimer’s Justin Kim neither of these events are directly related to why he recently upgraded Aurinia’s rating from Perform (i.e., Hold) to Outperform (i.e., Buy).
https://www.tipranks.com/news/article/aurinia-long-term-prospects-are-sound-says-oppenheimer?utm_source=advfn.com&utm_medium=referral